Urine and serum concentrations of inhaled and oral terbutaline
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Urine and serum concentrations of inhaled and oral terbutaline. / Elers, Jimmi; Hostrup, Morten; Pedersen, Lars; Henninge, John; Hemmersbach, Peter; Dalhoff, Kim; Backer, Vibeke.
In: International Journal of Sports Medicine, Vol. 33, No. 12, 2012, p. 1026-1033.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Urine and serum concentrations of inhaled and oral terbutaline
AU - Elers, Jimmi
AU - Hostrup, Morten
AU - Pedersen, Lars
AU - Henninge, John
AU - Hemmersbach, Peter
AU - Dalhoff, Kim
AU - Backer, Vibeke
N1 - CURIS 2012 5200 129
PY - 2012
Y1 - 2012
N2 - We examined urine and serum concentrations after therapeutic use of single and repetitive doses of inhaled and supratherapeutic oral use of terbutaline. We compared the concentrations in 10 asthmatics and 10 healthy subjects in an open-label, cross-over study with 2 mg inhaled and 10 mg oral terbutaline on 2 study days. Further, 10 healthy subjects were administrated 1 mg inhaled terbutaline in 4 repetive doses with total 4 mg. Blood samples were collected at baseline and during 6 h after the first inhalations. Urine samples were collected at baseline and during 12 h after the first inhalations. Median (IQR) urine concentrations peaked in the period 0-4 h after inhalation with Cmax 472 (324) ng/mL in asthmatics and 661 (517) ng/mL in healthy subjects, and 4-8 h after oral use with Cmax 666 (877) ng/mL in asthmatic and 402 (663) ng/mL in healthy subjects. In conclusion we found no significant differences in urine and serum concentrations between asthmatic and healthy subjects. We compared urine and serum concentrations after therapeutic inhaled doses and supratherapeutic oral doses and observed significant statistical differences in both groups but found it impossible to distinguish between therapeutic and prohibited use based on doping tests with urine and blood samples.
AB - We examined urine and serum concentrations after therapeutic use of single and repetitive doses of inhaled and supratherapeutic oral use of terbutaline. We compared the concentrations in 10 asthmatics and 10 healthy subjects in an open-label, cross-over study with 2 mg inhaled and 10 mg oral terbutaline on 2 study days. Further, 10 healthy subjects were administrated 1 mg inhaled terbutaline in 4 repetive doses with total 4 mg. Blood samples were collected at baseline and during 6 h after the first inhalations. Urine samples were collected at baseline and during 12 h after the first inhalations. Median (IQR) urine concentrations peaked in the period 0-4 h after inhalation with Cmax 472 (324) ng/mL in asthmatics and 661 (517) ng/mL in healthy subjects, and 4-8 h after oral use with Cmax 666 (877) ng/mL in asthmatic and 402 (663) ng/mL in healthy subjects. In conclusion we found no significant differences in urine and serum concentrations between asthmatic and healthy subjects. We compared urine and serum concentrations after therapeutic inhaled doses and supratherapeutic oral doses and observed significant statistical differences in both groups but found it impossible to distinguish between therapeutic and prohibited use based on doping tests with urine and blood samples.
U2 - 10.1055/s-0032-1311590
DO - 10.1055/s-0032-1311590
M3 - Journal article
C2 - 22782385
VL - 33
SP - 1026
EP - 1033
JO - International Journal of Sports Medicine
JF - International Journal of Sports Medicine
SN - 0172-4622
IS - 12
ER -
ID: 43856683